Advertisement
Articles
Advertisement

Focus on Outsourcing 12/22/06

Fri, 12/22/2006 - 6:16am
Lonza to License Gene Expression System to Roche
Lonza Group, Basel, Switzerland, will license its GS (glutamine synthetase) expression system and GS-CHO protein free system to Roche, also Basel, as a platform for different applications within its research and development centers.
Full Article

Schering-Plough Licenses Worldwide Rights to Pradefovir
Schering-Plough Corp., Kenilworth, N.J., signed licensing agreements with Valeant Pharmaceuticals International, Costa Mesa, Calif., and Metabasis Therapeutics Inc., San Diego, Calif., for exclusive worldwide development and commercial rights to pradefovir, an investigational oral antiviral compound to treat chronic hepatitis B.
Full Article

Sangamo and City of Hope Collaborate on Brain Cancer Treatment
Sangamo BioSciences Inc., Richmond, Calif., has entered into an exclusive, worldwide license agreement with City of Hope, Duarte, Calif., for intellectual property related to a chimeric immunoreceptor useful in treating human cancers.
Full Article

Merck and Idera Sign Agreement for Toll-like Receptor Agonists
Merck & Co., Inc., Whitehouse Station, N.J., and Idera Pharmaceuticals, Cambridge, Mass. formed a broad collaboration to research, develop, and commercialize Idera’s Toll-like Receptor agonists by incorporating them in therapeutic and prophylactic vaccines being developed by Merck for oncology, infectious diseases, and Alzheimer’s disease.
Full Article

Genentech and AC Immune Sign License for Alzheimer Therapy
AC Immune, Ltd., Lausanne, Switzerland, has entered into an exclusive global license agreement and research collaboration with Genentech Inc., South San Francisco, to develop anti-beta-amyloid antibodies to treat Alzheimer's and other diseases.
Full Article

Roche to Use Halozyme Technology to Improve Drug Delivery
Halozyme Therapeutics Inc., San Diego, and Roche, Basel, Switzerland, have entered into an agreement to apply Halozyme's Enhanze technology, a proprietary drug delivery technology, to Roche's biological therapeutic compounds.
Full Article

Archemix Grants Ribomic a License for Aptamer-Based Reagents
Archemix Corp., Cambridge, Mass., granted Ribomic Inc., Tokyo, Japan, a worldwide, non-exclusive, royalty-bearing license for the use of an IgG aptamer for affinity purification uses.
Full Article

Biota and Boehringer Ingelheim Enter Licence for HCV Program
Biota Holdings Ltd., Notting Hill, Australia, entered into a worldwide research collaboration and licensing agreement with Boehringer Ingelheim, Ingelheim, Germany, to develop and commercialize Biota’s novel nucleoside analogues designed to treat hepatitis C virus (HCV) infections and other diseases.
Full Article

Neurogen In-licenses Drug Candidate for Parkinson's Disease
Neurogen Corp., Branford, Conn., has acquired from Wyeth Pharmaceuticals, Madison, N.J., worldwide development and commercialization rights to Aplindore, a small molecule partial agonist for the D2 dopamine receptor, which it plans to take to phase II trials in Parkinson's disease and restless legs syndrome in 2007.
Full Article

Inovio Grants VGX License to Develop Novel Cancer Therapeutic
Inovio Biomedical Corp., San Diego, Calif., has granted VGX Pharmaceuticals, Blue Bell, Pa., a worldwide non-exclusive license to its DNA delivery technology for intratumoral delivery of a proprietary gene to control the growth of melanoma and other cancers.
Full Article

Nastech Licenses RNAi Technology from City of Hope
Nastech Pharmaceutical Co. Inc., Bothell, Wash. has entered into a license agreement with City of Hope, Duarte, Calif., for rights to Dicer-Substrate RNA interference intellectual property and technology, which may offer increased potency for drug development.
Full Article

Ablynx Enters License Agreement with Wyeth
Ablynx, Ghent, Belgium, entered into an exclusive license agreement with Wyeth Pharmaceuticals, Madison, N.J., to discover, develop, and commercialize Nanobodies directed at the tumour necrosis factor alpha protein and its receptors that target diseases in multiple therapeutic areas.
Full Article

Introgen Obtains Exclusive License to Family of Therapies
Introgen Therapeutics Inc., Austin, Texas, has obtained a worldwide, exclusive license to a family of patent applications directed to combination therapy using Advexin with inhibitors of epidermal growth factor receptors from The University of Texas System M. D. Anderson Cancer Center.
Full Article


Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading